ENRIQUE MARÍA
OCIO SAN MIGUEL
Investigador en el periodo 2013-2018
University of Turin
Turín, ItaliaPublicaciones en colaboración con investigadores/as de University of Turin (9)
2023
2022
-
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
Leukemia, Vol. 36, Núm. 5, pp. 1371-1376
-
Melflufen for the treatment of multiple myeloma
Expert Review of Clinical Pharmacology
2021
-
6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival
British Journal of Haematology, Vol. 192, Núm. 5, pp. 843-852
2020
-
Melflufen: A peptide–drug conjugate for the treatment of multiple myeloma
Journal of Clinical Medicine, Vol. 9, Núm. 10, pp. 1-16
2019
-
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
The Lancet Haematology, Vol. 6, Núm. 9, pp. e459-e469
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
-
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): A phase 3b study in refractory multiple myeloma
Blood, Vol. 128, Núm. 4, pp. 497-503
2014
-
New drugs and novel mechanisms of action in multiple myeloma in 2013: A report from the International Myeloma Working Group (IMWG)
Leukemia, Vol. 28, Núm. 3, pp. 525-542